Left atrial appendage closure—promise meets proof, and proof meets pause.

In The New England Journal of Medicine, two pivotal trials draw a nuanced arc:

CHAMPION-AF shows noninferior stroke prevention with less bleeding vs direct oral anticoagulants, while CLOSURE-AF tempers enthusiasm—failing noninferiority in older, high-risk patients with meaningful procedural risk.

The message is elegant and sobering: innovation must bow to evidence, and patient selection remains paramount.

In atrial fibrillation, the art lies not in closing the appendage—but in opening judgment.